Balazs Halmos, MD, MS, Montefiore Einstein Center for Cancer Care

Articles

Updates on I/O Therapy for Non-Driver mNSCLC

September 1st 2020

EGFR Exon 20 Mutations in NSCLC

September 1st 2020

KRAS-Mutant NSCLC

September 1st 2020

HER2 Targeted Therapy for Treatment of NSCLC

September 1st 2020

MET Exon 14 Mutations in mNSCLC

September 1st 2020

RET Fusion+ mNSCLC

September 1st 2020

Dr. Halmos on the Importance of Identifying Biomarkers in Advanced NSCLC

July 9th 2020

Balazs Halmos, MD, MS, discusses the importance of identifying biomarkers in advanced non–small cell lung cancer.

Dr. Halmos on Recent Advancements in Non–Small Cell Lung Cancer

June 23rd 2020

Balazs Halmos, MD, MS, discusses recent advancements made in non–small cell lung cancer.

Dr. Halmos on Actionable Biomarkers in NSCLC

November 12th 2019

Balazs Halmos, MD, MS, discusses actionable biomarkers in patients with oncogene-driven non–small cell lung cancer.

Dr. Halmos on Second-Line Treatment in Metastatic Squamous NSCLC

November 2nd 2018

Balazs Halmos, MD, MS, director of thoracic oncology and director of clinical cancer genomics, Montefiore Medical Center, discusses second-line treatment for patients with metastatic squamous non–small cell lung cancer (NSCLC).

Dr. Halmos on Immunotherapy in Squamous NSCLC

October 18th 2018

Balazs Halmos, MD, MS, director of thoracic oncology and director of clinical cancer genomics, Montefiore Medical Center, discusses the use of immunotherapy in the treatment of patients with metastatic squamous non–small cell lung cancer (NSCLC).